BioWa Inc., (Princeton, NJ) has entered into a second agreement with MedImmune to provide additional access to BioWa’s patented Potelligent technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
BioWa Inc., (Princeton, NJ) has entered into a second agreement with MedImmune to provide additional access to BioWa’s patented Potelligent technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
The agreement grants to MedImmune nonexclusive license rights to develop, manufacture, and market antibodies based on Potelligent technology for an undisclosed number of targets. In return, BioWa will receive certain fees and milestone payments from MedImmune during product development and royalties on marketed products using ADCC enhanced antibodies.
Potelligent technology is designed to improve the potency and efficacy of antibody therapeutics by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of antibody therapeutics. Potelligent technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that Potelligent technology significantly enhances ADCC activity of an antibody in vitro, thereby increasing the potential for improved activity in vivo.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
INTERPHEX 2025: Critical Role of Walk-In Chambers in Bio/Pharma Development and Manufacturing
April 3rd 2025Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, sat down with the PharmTech Group at INTERPHEX 2025 to discuss the design and critical role of walk-in chambers in the bio/pharmaceutical industry.